{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:10Z","timestamp":1790742010346,"version":"4.1.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.phrs.2020.105120","type":"journal-article","created":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T10:37:25Z","timestamp":1596969445000},"page":"105120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Biological therapy in pediatric age"],"prefix":"10.1016","volume":"161","author":[{"given":"Francesca","family":"Penagini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cococcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Dilillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Vincenzo","family":"Zuccotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105120_bib0005","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn\u2019s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","author":"Ruemmele","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0015","doi-asserted-by":"crossref","DOI":"10.1067\/mpd.2000.107161","article-title":"Use of infliximab in the treatment of Crohn\u2019s disease in children and adolescents","author":"Hyams","year":"2000","journal-title":"J. Pediatr."},{"key":"10.1016\/j.phrs.2020.105120_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/j.1572-0241.2003.07343.x","article-title":"Infliximab (REMICADE) therapy in the treatment of pediatric Crohn\u2019s disease","author":"Baldassano","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0025","article-title":"A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease","author":"Cezard","year":"2003","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000000045","article-title":"Mucosal healing in pediatric Crohn\u2019s disease after anti-TNF therapy: a long-term experience at a single center","author":"Nobile","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2013.12.017","article-title":"Predictors of response to Infliximab in children with luminal Crohn\u2019s disease","author":"Grover","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000083","article-title":"Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn\u2019s disease","author":"Church","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0045","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0b013e3181a70f21","article-title":"Infliximab therapy in children with concurrent perianal crohn disease: observations from REACH","author":"Crandall","year":"2009","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/apt.12928","article-title":"Predictors of response to infliximab in paediatric perianal Crohn\u2019s disease","author":"Dupont-Lucas","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0055","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izy217","article-title":"Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn\u2019s disease in children","author":"El-Matary","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0060","doi-asserted-by":"crossref","DOI":"10.1097\/01.mpg.0000237933.38223.da","article-title":"Infliximab in pediatric Crohn disease patients with enterovesicular fistulas","author":"Teitelbaum","year":"2007","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/j.1651-2227.2010.01731.x","article-title":"Recognition and treatment of genitourinary complications in paediatric Crohn\u2019s disease using Infliximab","author":"Afzal","year":"2010","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"10.1016\/j.phrs.2020.105120_bib0070","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000000533","article-title":"Infliximab therapy in pediatric patients 7 years of age and younger","author":"Kelsen","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0075","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000002112","article-title":"Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study","author":"Naviglio","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","author":"Hyams","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0085","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21383","article-title":"Acute severe ulcerative colitis in children: a systematic review","author":"Turner","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2009.759","article-title":"Outcome following infliximab therapy in children with ulcerative colitis","author":"Hyams","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0095","doi-asserted-by":"crossref","DOI":"10.1097\/01.MIB.0000160803.44449.a5","article-title":"Infliximab efficacy in pediatric ulcerative colitis","author":"Eidelwein","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0100","article-title":"Infliximab in pediatric ulcerative colitis: two-year follow-up","author":"Mamula","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0105","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.02.047","article-title":"Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response","author":"Turner","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/S1590-8658(02)80058-5","article-title":"Severe attack of ulcerative colitis in children: retrospective clinical survey","author":"Barabino","year":"2002","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2015.01.156","article-title":"Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: efficacy of infliximab as a rescue therapy","author":"Aloi","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0120","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0b013e31828133d6","article-title":"Contemporary outcomes for ulcerative colitis inpatients admitted to pediatric hospitals in the United Kingdom","author":"Russell","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0125","first-page":"13","article-title":"The availability of calcineurin inhibitors and infliximab in acute severe colitis have reduced colectomy rates in 283 children admitted during 1990-2012","volume":"62","author":"Sapir Choshen","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0130","doi-asserted-by":"crossref","DOI":"10.17219\/acem\/35802","article-title":"Induction & maintenance infliximab therapy in children with moderate to severe ulcerative colitis: retrospective, multicenter study","author":"Iwa\u0144czak","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0135","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13913","article-title":"Review article: dose optimisation of infliximab for acute severe ulcerative colitis","author":"Hindryckx","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0140","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.071","article-title":"Fecal infliximab loss","author":"Gibson","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0145","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13175","article-title":"Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis","author":"Rosen","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0150","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13631","article-title":"Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis","author":"Ungar","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0155","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","author":"Yarur","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105120_bib0160","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","author":"Gibson","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0170","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izx039","article-title":"Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis","author":"Shah","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0175","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.14072","article-title":"Predicting response after infliximab salvage in acute severe ulcerative colitis","author":"Choy","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0180","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz019","article-title":"Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis","author":"Church","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0185","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0190","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","author":"Miele","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2005.07.010","article-title":"Clinical and biological consequences of immunization to infliximab in pediatric Crohn\u2019s disease","author":"Candon","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2020.105120_bib0200","doi-asserted-by":"crossref","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium","author":"Jacobstein","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0205","doi-asserted-by":"crossref","DOI":"10.1002\/acr.20246","article-title":"Prevention of acute adverse events related to infliximab infusions in pediatric patients","author":"Lahdenne","year":"2010","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.phrs.2020.105120_bib0210","doi-asserted-by":"crossref","DOI":"10.1111\/j.1651-2227.2007.00042.x","article-title":"Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease","author":"Kolho","year":"2007","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"10.1016\/j.phrs.2020.105120_bib0215","article-title":"Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid","author":"H\u00e4m\u00e4l\u00e4inen","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0220","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2036.2003.01411.x","article-title":"Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model","author":"Crandall","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0225","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21871","article-title":"Antitumor necrosis factor treatment for pediatric inflammatory bowel disease","author":"De Bie","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","author":"Rahier","year":"2009","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0235","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0b013e3181957a11","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update","author":"MacKey","year":"2009","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0240","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin\u2019s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-\u03b1) inhibitors: results of the REFURBISH study","author":"Deepak","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0245","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0250","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000000713","article-title":"Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease","author":"Fumery","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0255","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000000589","article-title":"Adalimumab therapy in children with crohn disease previously treated with infliximab","author":"Cozijnsen","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0260","doi-asserted-by":"crossref","DOI":"10.2147\/BTT.S183088","article-title":"Efficacy of adalimumab as second-line therapy in a pediatric cohort of crohn\u2019s disease patients who failed infliximab therapy: the Italian society of pediatric gastroenterology, hepatology, and nutrition experience","author":"Alvisi","year":"2019","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0265","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2009.493","article-title":"Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric crohns disease","author":"Rosh","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2009.372","article-title":"Efficacy of adalimumab in moderate-to-severe pediatric crohn\u2019s disease","author":"Viola","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2010.04.002","article-title":"Long-term efficacy of adalimumab in Paediatric Crohn\u2019s disease patients na\u00efve to other anti-TNF therapies","author":"Mart\u00edn-de-Carpi","year":"2010","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0280","doi-asserted-by":"crossref","DOI":"10.4321\/S1130-01082013001000002","article-title":"Efficacy and safety of adalimumab in the treatment of Crohn\u2019s disease in children","author":"Navas-L\u00f3pez","year":"2013","journal-title":"Rev. Espa\u00f1ola Enfermedades Dig."},{"key":"10.1016\/j.phrs.2020.105120_bib0285","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe crohn\u2019s disease in children","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0290","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with Crohn\u2019s disease","author":"Faubion","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0295","doi-asserted-by":"crossref","DOI":"10.1097\/00054725-200407000-00024","article-title":"Mucosal healing in pediatric Crohn\u2019s disease: the goal of medical treatment","author":"D\u2019Haens","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2011.09.004","article-title":"The effects of anti-TNF-\u03b1 treatment with adalimumab on growth in children with Crohn\u2019s disease (CD)","author":"Malik","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0305","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20069","article-title":"Linear growth improves during infliximab therapy in children with chronically active severe Crohn\u2019s disease","author":"Walters","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0310","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0b013e3181edd797","article-title":"Improvement in growth of children with crohn disease following anti-TNF-\u03b1 therapy can be independent of pubertal progress and glucocorticoid reduction","author":"Malik","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease","author":"Ruemmele","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0320","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study","author":"Sharma","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0325","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from european Crohn\u2019s and colitis organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","author":"Turner","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0330","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2036.2011.04603.x","article-title":"A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of Adalimumab in children with inflammatory bowel disease","author":"Russell","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0335","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.20534","article-title":"Short-term response to Adalimumab in childhood inflammatory bowel disease","author":"Noe","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0340","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000003","article-title":"A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease","author":"Vahabnezhad","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0345","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000000470","article-title":"Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis","author":"Volonaki","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0350","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2009.177","article-title":"The natural history of pediatric ulcerative colitis: a population-based cohort study","author":"Gower-Rousseau","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2013.03.007","article-title":"Presenting features and disease course of pediatric ulcerative colitis","author":"Aloi","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0360","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13478","article-title":"Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies","author":"Fumery","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0365","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000001883","article-title":"Efficacy and safety of adalimumab in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD registry","author":"Aloi","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0370","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0b013e318174e886","article-title":"Safety and efficacy of adalimumab in pediatric patients with crohn disease","author":"Wyneski","year":"2008","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0375","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-009-0791-7","article-title":"Adalimumab treatment in children with refractory crohn\u2019s disease","author":"Rosenbach","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2020.105120_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosisfactor therapy for pediatric inflammatory bowel disease: a systematic review","author":"Dulai","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0385","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000001165","article-title":"Golimumab therapy in six patients with severe pediatric onset Crohn disease","author":"Merras-Salmio","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0390","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.phrs.2020.105120_bib0395","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","author":"Singh","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102529","article-title":"A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease","author":"Aardoom","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105120_bib0405","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000001262","article-title":"Subcutaneous golimumab in pediatric ulcerative colitis: pharmacokinetics and clinical benefit","author":"Hyams","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0410","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0415","doi-asserted-by":"crossref","DOI":"10.1111\/apt.14371","article-title":"Efficacy and safety of golimumab in Crohn\u2019s disease: a French national retrospective study","author":"Martineau","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0420","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0425","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1353","article-title":"Population pharmacokinetics and exposure-response modeling analyses of golimumab in children with moderately to severely active ulcerative colitis","author":"Xu","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105120_bib0430","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000001024","article-title":"Use of placebo in pediatric inflammatory bowel diseases: a position paper from ESPGHAN, ECCO, PIBDnet, and the canadian children IBD network","author":"Turner","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0435","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-018-00783-1","article-title":"Benefit\u2013Risk assessment of vedolizumab in the treatment of Crohn\u2019s disease and ulcerative colitis","author":"Battat","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2020.105120_bib0440","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-\u03b14\u03b27 integrin therapeutic antibody in development for inflammatory bowel diseases","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0445","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0450","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","author":"Fleisher","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2020.105120_bib0455","article-title":"321 vedolizumab use in pediatric patients with inflammatory bowel disease","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0460","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000918","article-title":"Vedolizumab therapy in severe pediatric inflammatory bowel disease","author":"Conrad","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0465","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000865","article-title":"Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease","author":"Singh","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0470","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx082","article-title":"Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN","author":"Ledder","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0475","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-018-0868-x","article-title":"Vedolizumab use after failure of TNF-\u03b1 antagonists in children and adolescents with inflammatory bowel disease","author":"Schneider","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0480","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","author":"Sands","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0485","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort","author":"Shelton","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpedsurg.2017.12.001","article-title":"Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab","author":"Zimmerman","year":"2018","journal-title":"J. Pediatr. Surg."},{"key":"10.1016\/j.phrs.2020.105120_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajhg.2009.01.026","article-title":"Diverse genome-wide association studies associate the IL12\/IL23 pathway with crohn disease","author":"Wang","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2020.105120_bib0500","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.phrs.2020.105120_bib0505","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","author":"Benson","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2020.105120_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(99)70392-6","article-title":"Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice","author":"Fuss","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0515","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","author":"Langley","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0520","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007572.pub3","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease","author":"Macdonald","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2020.105120_bib0525","doi-asserted-by":"crossref","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","author":"Neurath","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0530","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0535","doi-asserted-by":"crossref","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","author":"Sandborn","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0540","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0545","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0550","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.06.037","article-title":"Effects of ustekinumab on histologic disease activity in patients with Crohn\u2019s disease","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease","author":"Battat","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0560","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center","author":"Dayan","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0565","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy206","article-title":"Management of paediatric patients with medically refractory Crohn\u2019s disease using ustekinumab: a multi-centred cohort study","author":"Chavannes","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0570","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000000503","article-title":"Ustekinumab for resistant pediatric Crohn disease","author":"Rinawi","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","author":"Cantini","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2020.105120_bib0580","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.14816","article-title":"Ustekinumab for skin reactions associated with anti-tumor necrosis factor-\u03b1 agents in patients with inflammatory bowel diseases: a single-center retrospective study","author":"Ezzedine","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections","author":"Kaushik","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0590","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.1936","article-title":"Biosimilars-why terminology matters","author":"Weise","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2020.105120_bib0595","article-title":"Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-\u03b1 agent (infliximab), in inflammatory bowel diseases","author":"Komaki","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0600","doi-asserted-by":"crossref","DOI":"10.1007\/s40259-016-0206-1","article-title":"Infliximab biosimilars in the treatment of inflammatory bowel diseases: a systematic review","author":"Radin","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.phrs.2020.105120_bib0605","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000000903","article-title":"Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN paediatric IBD porto group","author":"De Ridder","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0610","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000001643","article-title":"Induction therapy with biosimilar infliximab in children with crohn disease","author":"Sieczkowska-Golub","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0615","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2017-313404","article-title":"Biosimilar infliximab use in paediatric IBD","author":"Richmond","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.phrs.2020.105120_bib0620","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000002011","article-title":"Use of infliximab biosimilar versus originator in a pediatric United Kingdom inflammatory bowel disease induction cohort","author":"Chanchlani","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0625","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.105120_bib0630","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","author":"Sieczkowska","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0635","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000002091","article-title":"Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful","author":"Gervais","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0640","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izx047","article-title":"Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study, in: inflamm","author":"Kang","year":"2018","journal-title":"J. Inflamm. Bowel Dis. Disord."},{"key":"10.1016\/j.phrs.2020.105120_bib0645","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000601","article-title":"Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease","author":"Van Hoeve","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2020.105120_bib0650","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-017-0529-x","article-title":"Assessing the value of biosimilars: a review of the role of budget impact analysis","author":"Simoens","year":"2017","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.phrs.2020.105120_bib0655","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-015-0233-1","article-title":"The budget impact of biosimilar infliximab (Remsima\u00ae) for the treatment of autoimmune diseases in five european countries","author":"Jha","year":"2015","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0660","article-title":"A budget impact model for biosimilar infliximab in Crohns disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia","author":"Brodszky","year":"2016","journal-title":"Expert Rev. Pharmacoeconomics Outcomes Res."},{"key":"10.1016\/j.phrs.2020.105120_bib0665","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000002141","article-title":"Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the pediatric IBD porto group of ESPGHAN","author":"de Ridder","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0670","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease - algorithm for practical management","author":"Ding","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.04.010","article-title":"Concomitant use of immunomodulators affects the durability of infliximab therapy in children with crohn\u2019s disease","author":"Grossi","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0680","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2036.2010.04507.x","article-title":"The duration of effect of infliximab maintenance treatment in paediatric Crohn\u2019s disease is limited","author":"De Bie","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0685","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v23.i3.414","article-title":"Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease","author":"Tighe","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0690","doi-asserted-by":"crossref","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease","author":"Mazor","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0695","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ibd\/izx065","article-title":"Combination immunosuppression in IBD","volume":"24","author":"Bots","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0700","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.07.021","article-title":"Anti\u2013tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis","author":"Bloemendaal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0705","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro","author":"Vos","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0710","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"AntiTumor necrosis factor-\u03b1 antibodies induce regulatory macrophages in an Fc region-dependent manner","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.earlhumdev.2010.01.018","article-title":"The infant intestinal microbiome: friend or foe?","author":"Mshvildadze","year":"2010","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.phrs.2020.105120_bib0720","doi-asserted-by":"crossref","DOI":"10.1038\/mi.2016.65","article-title":"The ATG16L1 risk allele associated with Crohn\u2019s disease results in a Rac1-dependent defect in dendritic cell migration that is corrected by thiopurines","author":"Wildenberg","year":"2017","journal-title":"Mucosal. Immunol."},{"key":"10.1016\/j.phrs.2020.105120_bib0725","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0730","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000001551","article-title":"Less anti-infliximab antibody formation in paediatric Crohn patients on concomitant immunomodulators","author":"Kansen","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","author":"Colombel","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0740","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjw086","article-title":"Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn\u2019s disease under combined immunosuppression: escalation versus early treatment","author":"Kang","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0745","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","author":"Singh","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0750","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izy010","article-title":"The impact of combination therapy on infliximab levels and antibodies in children and young adults with inflammatory bowel disease","author":"Chi","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0755","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","author":"Strik","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","author":"Ben-Horin","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0765","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0770","doi-asserted-by":"crossref","DOI":"10.1016\/S1873-9946(14)60561-4","article-title":"P441 Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in IBD patients","author":"van Schaik","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0775","doi-asserted-by":"crossref","DOI":"10.1111\/apt.15054","article-title":"The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn\u2019s disease: a post hoc analysis","author":"Hyams","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0780","article-title":"Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn\u2019s disease: a post hoc analysis of the PAILOT randomized controlled trial","author":"Matar","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0785","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","author":"Adedokun","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0790","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","author":"Schreiber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105120_bib0795","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izx104","article-title":"Malignancy and mortality in pediatric-onset inflammatory bowel disease: a systematic review","author":"Aardoom","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0800","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j3951","article-title":"Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014","author":"Ol\u00e9n","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2020.105120_bib0805","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in crohn\u2019s disease: results from the TREATTM registry","author":"Lichtenstein","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0810","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/apt.15637","article-title":"Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System","author":"Shah","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0815","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0820","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201710001-00694","article-title":"PYRAMID registry: long-term safety and effectiveness of adalimumab by baseline immunomodulator use in patients with Crohn\u02bcs disease","author":"Reinisch","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0825","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.10.028","article-title":"Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population","author":"Ol\u00e9n","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0830","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.21615","article-title":"Long-term outcome of treatment with infliximab in pediatric-onset Crohn\u2019s disease: a population-based study","author":"Cromb\u00e9","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0835","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","author":"Pasternak","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.phrs.2020.105120_bib0840","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0845","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/17474124.2019.1663173","article-title":"Infections and malignancies risks related to TNF-\u03b1-blocking agents in pediatric inflammatory bowel diseases","volume":"13","author":"Alvisi","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0850","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0855","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X13479826","article-title":"Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response","author":"Lichtenstein","year":"2013","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0860","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0b013e31829aad16","article-title":"Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease","author":"Dulai","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0865","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjw008","article-title":"Anti-TNF monotherapy for Crohn\u2019s disease: a 13-year multicentre experience","author":"Peyrin-Biroulet","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2020.105120_bib0875","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","author":"Gisbert","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2012.03.006","article-title":"Long-term outcome of tumor necrosis factor alpha antagonist\u2019s treatment in pediatric Crohn\u2019s disease","author":"Assa","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0885","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","author":"Stidham","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0890","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","author":"Ben-Horin","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0895","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","author":"Billioud","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0900","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0905","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","author":"Nanda","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0910","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","author":"Wang","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.phrs.2020.105120_bib0915","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0b013e32835558cf","article-title":"Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis","author":"Lee","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0920","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105120_bib0925","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","author":"Brandse","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0930","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/apt.14410","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib0935","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MPG.0000000000002051","article-title":"Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases","volume":"67","author":"Ungar","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.phrs.2020.105120_bib0940","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","author":"Afif","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0945","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105120_bib0950","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0955","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.11.046","article-title":"Mucosal healing and long-term outcomes of patients with inflammatory bowel diseases receiving clinic-based vs trough concentration-based dosing of infliximab","author":"Pouillon","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105120_bib0965","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0970","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izy203","article-title":"Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD","author":"Lega","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0975","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib0980","article-title":"Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease","author":"Lyles","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105120_bib0985","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz041","article-title":"Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease","author":"Ungaro","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.phrs.2020.105120_bib0990","doi-asserted-by":"crossref","DOI":"10.1080\/00365521.2018.1452974","article-title":"A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients","author":"Schulze","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105120_bib0995","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(16)31427-5","article-title":"Sa1939 serum vedolizumab assay at week 6 predicts sustained clinical remission and lack of recourse to optimisation in IBD","author":"Paul","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105120_bib1000","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib1005","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13276","article-title":"Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy","author":"Gisbert","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib1010","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13547","article-title":"Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis","author":"Kennedy","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105120_bib1015","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2019exit strategies\u2019] in inflammatory bowel disease","author":"Doherty","year":"2018","journal-title":"J. Crohn\u2019s Colitis"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820314286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820314286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:16:38Z","timestamp":1760912198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820314286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":203,"alternative-id":["S1043661820314286"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105120","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological therapy in pediatric age","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105120"}}